Can Your Patient Start Eating?
Yes, your patient can start eating now. The traditional criteria for DKA resolution have been met with anion gap closure to 14 (normal <12-14), and while beta-hydroxybutyrate remains mildly elevated at 2.57 mmol/L, this does not preclude oral intake 1.
Key Decision Points
Traditional DKA Resolution Criteria
The American Diabetes Association guidelines define DKA resolution as:
- Anion gap ≤12-14 (your patient: 14 ✓)
- pH >7.3
- Bicarbonate >15-18 mEq/L
Your patient has achieved anion gap closure, which is the primary marker used clinically 1.
The Beta-Hydroxybutyrate Controversy
Important nuance: While newer data suggest beta-hydroxybutyrate may be a more physiologically accurate marker, recent research shows this can actually delay appropriate transition to subcutaneous insulin without improving outcomes 2. In a 2026 study comparing beta-hydroxybutyrate-guided versus anion gap-guided management:
- Anion gap monitoring led to transition at median 13.3 hours
- Beta-hydroxybutyrate monitoring delayed transition to 23.5 hours
- No difference in DKA recurrence rates between groups 2
Persistent Beta-Hydroxybutyrate is Expected
Beta-hydroxybutyrate at 2.57 mmol/L (down from 7.5) represents excellent improvement. Complete normalization (<0.6 mmol/L) often lags behind clinical resolution 3. This persistent elevation does not indicate ongoing ketoacidosis requiring continued fasting.
Practical Management Algorithm
Proceed with oral intake when:
- ✓ Anion gap normalized or near-normal (your patient: 14)
- ✓ Patient is alert and able to eat safely
- ✓ No nausea/vomiting
- ✓ Beta-hydroxybutyrate trending down significantly (7.5→2.57 represents 66% reduction)
Transition protocol:
- Start oral intake now
- Administer subcutaneous long-acting insulin 2-4 hours before stopping IV insulin to prevent rebound ketoacidosis 1
- Continue IV insulin until patient tolerates oral intake and subcutaneous insulin has been given
Common Pitfalls to Avoid
Do not wait for beta-hydroxybutyrate to completely normalize - this unnecessarily prolongs IV insulin therapy and hospital stay without clinical benefit 2. The dramatic improvement from 7.5 to 2.57 mmol/L indicates resolution of the acute ketotic state.
Do not stop IV insulin abruptly - overlap with subcutaneous basal insulin by 2-4 hours is critical to prevent recurrent ketoacidosis 1.
In euglycemic DKA specifically, maintaining adequate dextrose-containing fluids while continuing insulin is essential during the transition period to prevent hypoglycemia while clearing remaining ketones.